Search
Search Results
-
Immunoregulatory cyclophilin a improves low-dose chemotherapy with a modulation of the immune tumor microenvironment in experimental models of melanoma B16 and lymphoma EL4 in vivo
PurposeDifferent regimens of low-dose chemotherapy (LDC) are currently being actively developed and introduced into clinical practice. Along with its...
-
Analysis of cost-effectiveness of chemotherapeutic agents and new therapies for the management of unresectable and metastatic melanoma
BackgroundThe advent of targeted therapies and immunotherapies has revolutionized metastatic melanoma (MM) management but their use is associated...
-
Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China
BackgroundDoxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) has been regarded as the standard treatment regimen for classical Hodgkin...
-
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
Engineered cytokine products represent promising agents for the treatment of immunogenic tumors, such as malignant melanoma, in addition to immune...
-
A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma
ObjectiveEndoplasmic reticulum stress (ERS) and long non-coding RNAs (lncRNAs) are important in melanoma development and progression. This study...
-
Successful clinical approach to the metastatic uterine leiomyosarcoma to the epicardium—a case report
BackgroundUterine leiomyosarcoma is a rare and aggressive tumour with a poor prognosis. Its metastases to the heart are even rarer, especially to the...
-
Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data
Background. Mucosal melanoma is rare and has distinct clinical and genetic features. Even with advances in targeted and immune therapies, the...
-
Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study
PurposeThis study retrospectively analyzed the risk factors for transchemotherapy dysgeusia.
MethodsBefore each chemotherapy cycle, patients were...
-
New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach
Purpose of ReviewMultiple therapies with novel mechanisms have been explored in clinical trials for the treatment of metastatic pheochromocytomas and...
-
Serum thymus and activation-regulated chemokine (TARC) levels in newly diagnosed patients with Hodgkin lymphoma: a new promising and predictive tool? Preliminary report
Thymus and activation-regulated chemokine (TARC) is expressed on Reed-Sternberg cells of patients with classical Hodgkin lymphoma (HL) and may serve...
-
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents
PurposeThis systematic review updates the MASCC/ESMO recommendations for high-emetic-risk chemotherapy (HEC) published in 2016–2017. HEC still...
-
Treatment outcomes and prognostic factors in 47 patients with primary anorectal malignant melanoma in the immune therapy era
PurposePrimary anorectal melanoma (ARM) accounts for approximately 1.2% of all melanomas and 16.5% of all mucosal melanomas. ARM is associated with...
